

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Aaron GARZON et al.

Confirmation No.: 9969

Application No.: 10/602,745

Patent No.: 7,235,584 B2

Filing Date: June 25, 2003

Patent Date: June 26, 2007

For: NON-PSYCHOTROPIC CANNABINOIDS

Attorney Docket No.: 87754-7499

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are listed on the attached Form PTO-1050. The corrections requested are as follows:

Column 59:

Line 43 (claim 6, line 11), before “optionally further substituted” change “terrahydropyran,” to -- tetrahydropyran, --. Support for this change appears in application claim 6.

Column 62:

Line 4 (claim 15, line 13), before “alkyloxy” change “C₁₋₆” to -- C₁₋₆ --. Support for this change appears in application claim 15.


Line 30 (claim 19, line 4), after “solution prepared” change “wit” to -- with --. Support for this change appears in application claim 19.

The requested corrections are for errors that appear to have been made by the Office. Therefore, no fee is believed to be due for this request. Should any fees be required, however,

please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

7-10-07
Date


Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP
Customer No. 28765

212-294-3311

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO.: 7,235,584 B2
APPLICATION NO.: 10/602,745
DATED: June 26, 2007
INVENTOR(S): Garzon et al.

Page 1 of 1

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 59:

Line 43 (claim 6, line 11), before "optionally further substituted" change "terahdropyran," to -- tetrahydropyran, --.

Column 62:

Line 4 (claim 15, line 13), before "alkyloxy" change "C₁₋₆" to -- C₁₋₆ --.

Line 30 (claim 19, line 4), after "solution prepared" change "wit" to -- with --.

59

substituted at the terminal carbon atom by a phenyl group, or (c) $-(CH_2)_nOR''$ wherein n is an integer of 1 to 7 and R'' is hydrogen or C₁-C₆ alkyl;

with the proviso that R₁ is other than a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue.

2. The compound according to claim 1 wherein R₁ is a saturated or unsaturated cyclic moiety, an aromatic moiety or a heterocyclic moiety having from 5-20 atoms comprising one or two-ringed structures, wherein each ring comprises 3-8 carbons and 0-4 heteroatoms, said heteroatoms each independently selected from the group consisting of N, O, and S; optionally further substituted with at least one substituent selected from the group consisting of lower alkyl, halogen, nitro, cyano, $-SR''$, $-NHR''$, $-N(R'')_2$, $-OR''$, $-COR''$, $-C(O)OR''$ or $NH-CUR''$ moiety wherein R'' is hydrogen or C₁-C₆ alkyl.

3. The compound according to claim 1 wherein R₁ is a heterocyclic moiety selected from the group consisting of an imidazolyl, an imidazolyl, a morpholino, a piperidyl, a piperazinyl, a pyrazolyl, a pyrrolyl, a pyrrolidinyl, a triazolyl, and a tetrazolyl, optionally further substituted wherein the substituent is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, keto, carboxy, or nitro, wherein C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ alkylthio are intended to include saturated and unsaturated linear, branched and cyclic structures.

4. The compound according to claim 1 wherein R₁ is imidazolyl, pyrazolyl, 2-methyl thio-2-imidazolyl, or 4-methylpiperidinyl.

5. The compound according to claim 1 wherein A—B is a 6(1) double bond and G is $-OH$ or lower acyloxy.

6. The compound according to claim 5 wherein R₂ is 1,1-dimethylheptyl or 1,2-dimethylheptyl and wherein R₁ is selected from the group consisting of imidazole, pyrazole, oxazole, isoxazole, tetrahydropyridine, pyrazoline, oxazoline, pyrrolidine, imidazoline, 2-thio-imidazole, 2-methylthio-imidazoline, 4-methyl-2-imidazoline, 4,4-dimethyl-2-imidazoline, methyl sulfide, methylsulfoxide, acetamido, benzamide, cyano, 1,2,4-triazole, 1,3,4-triazole, 1,2,3,4-tetrazole, 1,2,3,5-tetrazole, thiophene, phenyl, morpholine, thiomorpholine, thiazolidine, glycerol, piperazine, piperidine and tetrahydropyran, optionally further substituted wherein the substituent is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, keto, carboxy, or nitro, wherein C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ alkylthio are intended to include saturated and unsaturated linear, branched and cyclic structures.

7. The compound according to claim 6 wherein R₁ is imidazole, pyrazole, 2-methyl thio-2-imidazoline, or 4-methylpiperidine.


8. The compound according to claim 1 wherein A—B is absent and G is $-OH$ or lower acyloxy.

9. The compounds according to claim 1 selected from the group consisting of: (+)-(3 S,4 S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(imidazolomethyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran; (+)-(3S,4 S)-6,6-Dimethyl -dimethylheptyl)-1-hydroxy-9-(pyrazolomethyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran; (+)-(3S,4 S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(1H-imidazol-2-ylsulfanyl methyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran; (+)-(3S,4S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(4-piperidinopiperidine methyl)-6a, 7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran; and (+)-(3S,4S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(4-methylpiperidine methyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran

tetrahydropyran,

60

10. A pharmaceutical composition comprising as an active ingredient a compound of the general formula (I):



having the (3S,4S) configuration and being essentially free of the (3R,4R) enantiomer, wherein A—B indicates an optional 1(2) or 6(1) double bond,

R₁ is

A) R₃ where R₃ is selected from the group consisting of

a) a linear or branched, saturated or unsaturated, carbon side chain comprising 1-8 carbon atoms and 1-3 heteroatoms, at least one heteroatom being placed between two carbon atoms; or

b) a saturated or unsaturated cyclic moiety or an aromatic or heterocyclic moiety having from 5-20 atoms comprising one or two-ringed structures, wherein each ring comprises 3-8 carbons and 0-4 heteroatoms, said heteroatoms each independently selected from the group consisting of N, O, and S; wherein each ring optionally is further substituted with one or more groups selected from

- i) C₁₋₆ alkyl,
- ii) C₁₋₆ alkoxy,
- iii) C₁₋₆ alkylthio,
- iv) halo,
- v) carboxyl,
- vi) $-CO_2-C_{1-4}$ alkyl,
- vii) keto,
- viii) nitro, and

ix) a saturated or unsaturated cyclic moiety, or an aromatic or a heterocyclic moiety comprising one or two ringed structures wherein each ring comprises 3-8 carbons and 0-4 heteroatoms, said heteroatoms each independently selected from the group consisting of N, O, and S; wherein each ring optionally is further substituted with one or more groups selected from i)-viii) as defined above;

B) an amine or an amide substituted with at least one substituent as defined in R₃ above;

C) a thiol, a sulfide, a sulfoxide, a sulfone, a thioester or a thioamide optionally substituted with one substituent as defined in R₃ above; or

D) an ether $-OR_3$ wherein R₃ is as defined above;

G is (a) halogen, (b) C₁-C₆ alkyl, or (c) $-OR$ wherein R is (a') $-R''$, wherein R'' is hydrogen or C₁-C₆ alkyl optionally containing a terminal $-OR''$ or $-OC(O)R''$ moiety wherein R'' is hydrogen or C₁-C₆ alkyl, or (b') $-C(O)R''$ wherein R'' is as previously defined, and

R₂ is (a) C₁-C₁₂ alkyl, (b) $-OR''$, in which R'' is a straight chain or branched C₂-C₉ alkyl which may be substituted at the terminal carbon atom by a phenyl group, or (c) $-(CH_2)_nOR''$ wherein n is an integer of 1 to 7 and R'' is hydrogen or C₁-C₆ alkyl; with the proviso that R₁ is other than a heterocyclic moiety having a labile hydrogen atom so

61

that said moiety acts as a carboxylic acid analogue; together with a pharmaceutically acceptable diluent or carrier.

11. The composition according to claim 10 wherein R_1 is a saturated or unsaturated cyclic moiety, an aromatic moiety or a heterocyclic moiety having from 5–20 atoms comprising one or two-ringed structures, wherein each ring comprises 3–8 carbons and 0–4 heteroatoms, said heteroatoms each independently selected from the group consisting of N, O, and S; optionally further substituted with at least one substituent selected from the group consisting of lower alkyl, halogen, nitro, cyano, $-SR'''$, $-NHR'''$, $-N(R''')_2$, $-OR'''$, $-COR'''$, $-C(O)OR'''$ or $NH-COR'''$ moiety wherein R''' is hydrogen or C_1-C_6 alkyl.

12. The composition according to claim 10 wherein R_1 is a heterocyclic moiety selected from the group consisting of an imidazolyl, an imidazoliny, a morpholino, a piperidyl, a piperazinyl, a pyrazolyl, a pyrrolyl, a pyrrolidinyl, a triazolyl, and a tetrazolyl, optionally further substituted wherein the substituent is selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylthio, keto, carboxy, or nitro, wherein C_{1-6} alkyl, C_{1-6} alkoxy and C_{1-6} alkylthio are intended to include saturated and unsaturated linear, branched and cyclic structures.

13. The composition according to claim 10 wherein R_1 is imidazolyl, pyrazolyl, 2-methyl thio-2-imidazoliny, or 4-methylpiperidinyl.

14. The composition according to claim 10, wherein A—B is a 6(1) double bond, and G is $-OH$ or lower acyloxy.

15. The composition according to claim 14 wherein R_2 is 1,1-dimethylheptyl or 1,2-dimethylheptyl and wherein R_1 is selected from the group consisting of imidazole, pyrazole, oxazole, isoxazole, tetrahydropyridine, pyrazoline, oxazoline, pyrrolidine, imidazoline, 2-thio-imidazole, 2-methylthio-imidazoline, 4-methyl-2-imidazoline, 4,4-dimethyl-2-imidazoline, methyl sulfide, methylsulfoxide, acetamido, benzamide, cyano, 1,2,4-triazole, 1,3,4-triazole, 1,2,3,4-tetrazole, 1,2,3,5-tetrazole, thiophene, phenyl, morpholine,

62

thiomorpholine, thiazolidine, glycerol, piperazine, piperidine and tetrahydropyran, optionally further substituted wherein the substituent is selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylthio, keto, carboxy, or nitro, wherein C_{1-6} alkyl, C_{1-6} alkoxy and C_{1-6} alkylthio are intended to include saturated and unsaturated linear, branched and cyclic structures.

16. The composition according to claim 15 wherein R_1 is imidazole, pyrazole, 2-methyl thio-2-imidazoline, or 4-methylpiperidine.

17. The composition according to claim 10 wherein A—B is absent and G is OH or a lower acyloxy group.

18. The composition according to claim 10 wherein the active ingredient is selected from the group consisting of: (+)-(3S,4S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(imidazolomethyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran; (+)-(3S,4S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(pyrazolomethyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran; (+)-(3S,4S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(1H-imidazol-2-ylsulfanyl methyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran; (+)-(3S,4S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(4-piperidinopiperidinomethyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran; and (+)-(3S,4S)-6,6-Dimethyl-(1,1-dimethylheptyl)-1-hydroxy-9-(4-methylpiperidine methyl)-6a,7,10,10a-tetrahydro-6H-dibenzo [b,d]pyran.

19. The composition according to claim 10 wherein the carrier or diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution prepared with natural or synthetic ionic or non-ionic surfactants, or a combination of such cosolvent and micellar solutions.

20. The composition according to claim 19 wherein the carrier is (a) a solution of ethanol, a surfactant, and water or (b) an emulsion comprising a triglycerides, lecithin, glycerol, an emulsifier, an antioxidant, and water.

* * * * *